BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1015@pharmaconomics
DTSTAMP:20260707T015747Z
DTSTART;VALUE=DATE:20260401
DTEND;VALUE=DATE:20260402
SUMMARY:INBX Phase 1 — ozekibart (INBRX-109)
DESCRIPTION:Phase 1 trial results for ozekibart (INBRX-109) in locally advanced or metastatic\, unresectable colorectal cancer (CRC) are due Apr 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm\n\nTrack it: https://pharmaconomics.com/e/1015
URL:https://pharmaconomics.com/e/1015
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:INBX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR